Trimethoprim/Sulfamethoxazole
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TMP-SMX |
|---|---|
| Type | Drug |
| Aliases | BactrimCo-trimoxazoleSeptraTMP-SMXТриметоприм/Сульфаметоксазол |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Folate antagonist combination antibiotic |
|---|---|
| Mechanism | Synergistic blockade of two sequential steps in bacterial folate synthesis (dihydropteroate synthase + dihydrofolate reductase). |
| Typical dosing | PJP prophylaxis: 80/400 mg PO daily OR 160/800 mg PO 3x/week |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
PJP prophylaxis indicated in patients receiving sustained immunosuppression (rituximab + chemotherapy combinations).
Used By
Supportive Care
SUP-PJP-PROPHYLAXIS- Pneumocystis jirovecii prophylaxis